JP-PAHT@EC2611A

CICC Initiates Coverage on Ping An Good Doctor with Outperform Rating

CICC Reaffirms Buy Rating on Ping An Good Doctor, Sets Target Price at 14.20 HKD

DAHUA CONCORD CUTS PEACE GOOD DOCTOR TARGET PRICE AND REVENUE FORECAST

UOB Kay Hian Maintains Buy Rating on Ping An Good Doctor and Sets Price Target

Morgan Stanley Maintains Hold Rating on Ping An Good Doctor, with a Target Price of HKD 16.80

Ping An Good Doctor Reports Revenue and Net Profit Growth

Ping An Good Doctor Technology Sees Q1 2026 Net Profit More Than Double

PA GOODDOCTOR FY2026 Q1 Earnings Release on April 23 Pre-Market (BJT)

Ping An Good Doctor and Roche Diagnostics Sign Deep Cooperation Agreement to Promote Early Recognition and Standardized Treatment of Alzheimer's Disease

Renaissance Reiterates Buy Rating on Ping An Good Doctor with Price Target of HKD 23.88

Jefferies Reiterates Hold Rating on Ping An Good Doctor

Fujireve Raises Ping An Good Doctor's Rating and Target Price

UBS Releases Ping An Good Doctor Earnings Report, Raises Earnings Forecast But Cuts Price Target

Ping An Good Doctor AI Contribution of 80 Million to Gross Profit Last Year, Plans for Increased AI Investment This Year

Ping An Good Doctor Technology Sees Significant Profit and Revenue Growth in 2025 Fiscal Year

PA GOODDOCTOR released FY2025 Q4 earnings on March 24 During-Market (BJT), actual revenue HKD 1.649 B, actual EPS HKD 0.0604

PA GOODDOCTOR released FY2025 earnings on March 24 During-Market (BJT), actual revenue HKD 5.976 B (forecast HKD 6.045 B), actual EPS HKD 0.1967 (forecast HKD 0.1272)

PA GOODDOCTOR released FY2025 9 Months earnings on March 24 Pre-Market (BJT), actual revenue HKD 4.33 B, actual EPS HKD 0.1324

PA GOODDOCTOR released FY2025 Q3 earnings on March 24 Pre-Market (BJT), actual revenue HKD 1.621 B, actual EPS HKD 0.0593

PA GOODDOCTOR to release FY2025 earnings report on March 24, during market hours (BJT), forecast revenue HKD 6.194 B, EPS HKD 0.1297

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

01833

02318

601318

CICC initiates coverage on PA GOODDOCTOR with an "outperform" rating and a target price of HKD 14.20, representing a 36.3% upside from the previous day's closing price. CICC believes that PA GOODDOCTOR, as the core of Ping An Group's healthcare and elderly care ecosystem, has shown significant results in its strategic transformation and has reached a profitability inflection point, with clear growth and profit potential in the future. Despite adjustments in the Hong Kong stock market, CICC believes that short-term fluctuations do not reflect the true situation of PA GOODDOCTOR, and its service network is a core competitive advantage

同壁财经

PA GOODDOCTOR

PING AN

Ping An

CICC

Hang Seng Index

Hang Seng TECH Index

PING AN-R

Ping An Insurance

The market value of the medical and elderly care sector exceeds one trillion, and China International Capital Corporation is optimistic about the HMO model of PA GOODDOCTOR despite the downturn

510660

589720

512010

516610

513120

159929

CICC has initiated coverage on PA GOODDOCTORwith an Outperform rating and a target price of HKD14.2. The report highlights the company's strategic transformation in healthcare and elderly care, achieving full-year profitability in 2024 and positive operating profit in 2025. CICC expects significant profit growth driven by AI enhancements and operational efficiencies, forecasting EPS of RMB0.2 and RMB0.29 for 2026 and 2027, respectively, with a CAGR of 28.3% from 2025 to 2027.

AASTOCKS News

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI 300 Health Care ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal 800 Health Care ETF

CICC Initiates PA GOODDOCTOR  with Outperform Rating, TP HKD14.2

CICC has reaffirmed a Buy rating on Ping An Healthcare and Technology Company (PANHF) with a price target of HK$14.20, while the shares closed at HK$10.12. The overall analyst consensus suggests a Moderate Buy rating with an average price target of HK$16.84.

Tip Ranks

CICC Reaffirms Their Buy Rating on Ping An Healthcare and Technology Company (PANHF)

Morgan Stanley has maintained a Hold rating on Ping An Healthcare and Technology Company (PANHF) with a price target of HK$16.80. The company's shares closed at HK$11.75. Despite this, the analyst consensus remains a Strong Buy, with a higher price target consensus of HK$17.23.

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Ping An Healthcare and Technology Company (PANHF) Receives a Hold from Morgan Stanley

UOB Kay Hian analyst maintained a Buy rating on Ping An Healthcare and Technology Company yesterday and set a price target of HK$14.50.Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ping An Healthcare and Technology Company with a HK$17.23 average price target.

UOB Kay Hian

Ping An Healthcare and Technology Company (PANHF) Receives a Buy from UOB Kay Hian

M Stanley reported that Ping An Healthcare and Technology's 1Q results indicate progress towards its full-year target, with revenue up 9.1% YoY to RMB1.16 billion and net profit soaring 138.4% YoY to RMB79.1 million. The company has over 7,500 paying users, a 89% YoY increase, and its AI doctor users reached 5.6 million. M Stanley maintains an "Equalweight" rating with a target price of HKD16.8.

M Stanley: Ping An Healthcare and Technology  1Q Results Show Operations Progressing Toward Full-Year Target, Rated "Equalweight"

UOB Kay Hian has cut the target price for Ping An Healthcare and Technologyfrom HKD17.5 to HKD14.5, despite reporting solid 1Q26 results with a 9.1% YoY revenue increase and a 45.8% YoY rise in adjusted net profit. The firm anticipates conservative mid-single-digit revenue growth in 2026, adjusting its forecast to 5.4% YoY. However, it projects a CAGR of 14% for revenue and 42% for adjusted net profit from 2026 to 2028, driven by corporate health management. The broker maintains a Buy rating.

United Overseas Bank (UOB)

UOB Kay Hian Cuts Ping An Healthcare and Technology  TP to HKD14.5; 1Q26 Results Solid

PING AN HEALTHCARE AND TECHNOLOGYsaw its share price drop nearly 5% despite reporting a 138.4% year-on-year increase in net profit for Q1, reaching RMB79.114 million. The stock opened 1.7% higher but fell to HKD11.18, down 4.85%. Revenue for the quarter was RMB1.159 billion, up 9.1% YoY, with a significant growth in corporate clients, serving over 7,500, a nearly 89% increase YoY. The company's corporate health management business also showed continued growth.

PING AN HEALTHCARE AND TECHNOLOGY  Slumps Nearly 5% Post-Results; 1Q Net Profit Surges 1.38x

Ping An Healthcare and Technology Company has relocated its Hong Kong office to the 40th Floor of Dah Sing Financial Centre, effective April 23, 2026. The company appointed Ms. Cheung Lai Ha as the new process agent, succeeding Ms. Yuen Wing Yan Winnie. This change aims to maintain regulatory compliance and legal communication with authorities. The latest analyst rating for the stock (HK:1833) is a Hold with a price target of HK$12.40, and the company focuses on digital healthcare solutions in mainland China and beyond.

Ping An Healthcare Shifts Hong Kong Office and Appoints New Process Agent

PA GOODDOCTOR-0.220 (-1.838%) Short selling $13.64M; Ratio 48.069% announced its results for 1Q26. Revenue rose 9.1% YoY to RMB1.159 billion. Net profit swelled 138.4% YoY to RMB79.114 million. Adjusted net profit climbed 45.8% YoY to RMB84.359 million.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-23 16:25.) AASTOCKS Financial News

PA GOODDOCTOR 1Q NP RMB79.114M, Up 138.4% YoY

$XTALPI(02228.HK) Goldman Sachs launched the &#34;China AI Healthcare Index&#34; today, with Pharmaron as the top-weighted stock $ALI HEALTH(00241.HK)$JD HEALTH(06618.HK)$PA GOODDOCTOR(01833.HK)$YIDU TECH(02158.HK)$MircroPort Medbot-B(02252.HK)

JP-PAHT@EC2611A(29311.HK)

The market value of the medical and elderly care sector exceeds one trillion, and China International Capital Corporation is optimistic about the HMO model of PA GOODDOCTOR despite the downturn

CICC Initiates PA GOODDOCTOR with Outperform Rating, TP HKD14.2

CICC Reaffirms Their Buy Rating on Ping An Healthcare and Technology Company (PANHF)

Ping An Healthcare and Technology Company (PANHF) Receives a Hold from Morgan Stanley

Ping An Healthcare and Technology Company (PANHF) Receives a Buy from UOB Kay Hian